Want to see JP:4587 full AI Analyst Report?
4587 Stock Chart & Stats
¥1114.00
¥16.20(1.72%)
At close: 4:00 PM EDT
¥1114.00
¥16.20(1.72%)
Day’s Range― - ―
52-Week Range¥906.40 - ¥1,793.00
Previous CloseN/A
Volume642.50K
Average Volume (3M)968.02K
Market Cap
¥137.68B
Enterprise Value¥128.95K
Total Cash (Recent Filing)¥23.60B
Total Debt (Recent Filing)¥15.69B
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Nov 05, 2026EPS Estimate
-7.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-28.11
Shares Outstanding130,010,400
10 Day Avg. Volume747,810
30 Day Avg. Volume968,016
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)4.16
Price to Sales (P/S)11.56
P/FCF Ratio-14.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,875.00Price Target Upside68.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)56.88
Revenue Forecast (FY)¥37.05B
Bulls Say, Bears Say
Bulls Say
Strong Revenue ReboundThe sharp TTM revenue rebound indicates renewed demand or program activity and provides a stronger base for operating leverage. If converted into sustainable revenue, this growth could improve the economics of PeptiDream’s partnered discovery model.
Proprietary Platform And PartnershipsThe proprietary peptide discovery platform supports a partnership-led model with potential upfront fees, research funding, milestones and royalties. Broad pharmaceutical collaboration can diversify development risk and create recurring long-term monetization opportunities.
Manageable LeverageModerate leverage and a sizable equity base provide financial flexibility while the company funds research and partnered programs. This balance-sheet position may help PeptiDream withstand volatility and reduce immediate dependence on additional debt financing.
Bears Say
Persistent LossesOngoing operating and net losses show that the recent revenue rebound has not yet translated into sustainable profitability. Continued losses could constrain internal pipeline investment, weaken returns and increase reliance on partners or external funding.
Negative Cash GenerationNegative operating and free cash flow indicate that current operations are consuming cash rather than funding research internally. Persistent cash burn raises funding risk and may force PeptiDream to reduce development activity or seek financing if profitability does not recover.
Volatile Earnings DurabilityThe shift from strong profitability to sustained losses highlights dependence on the timing and success of partnered programs, milestones or other irregular revenue. Such volatility makes it harder to assess the durability of earnings and plan long-term investment.
Peptidream News
4587 FAQ
What was Peptidream Inc.’s price range in the past 12 months?
Peptidream Inc. lowest stock price was ¥906.40 and its highest was ¥1793.00 in the past 12 months.
What is Peptidream Inc.’s market cap?
Peptidream Inc.’s market cap is ¥137.68B.
When is Peptidream Inc.’s upcoming earnings report date?
Peptidream Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 53 days.
How were Peptidream Inc.’s earnings last quarter?
Peptidream Inc. released its earnings results on Aug 12, 2026. The company reported -¥8.89 earnings per share for the quarter, missing the consensus estimate of -¥3.19 by -¥5.7.
Is Peptidream Inc. overvalued?
According to Wall Street analysts Peptidream Inc.’s price is currently Undervalued.
Does Peptidream Inc. pay dividends?
Peptidream Inc. does not currently pay dividends.
What is Peptidream Inc.’s EPS estimate?
Peptidream Inc.’s EPS estimate is -7.01.
How many shares outstanding does Peptidream Inc. have?
Peptidream Inc. has 130,010,400 shares outstanding.
What happened to Peptidream Inc.’s price movement after its last earnings report?
Peptidream Inc. reported an EPS of -¥8.89 in its last earnings report, missing expectations of -¥3.19. Following the earnings report the stock price went up 1.492%.
Which hedge fund is a major shareholder of Peptidream Inc.?
Currently, no hedge funds are holding shares in JP:4587
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Peptidream Inc.
PeptiDream Inc. functions as a biopharmaceutical enterprise, concentrating on the identification and progression of therapeutic compounds such as constrained peptides, small molecules, and peptide-drug conjugates. The company's unique product pipeline is underpinned by its proprietary Peptide Discovery Platform System (PDPS), an advanced technology specifically designed for the development of peptide-based drugs. Additionally, PeptiDream maintains an exclusive licensing and collaborative research partnership with Takeda Pharmaceutical Company Limited, aimed at creating peptide drug conjugates for the treatment of neuromuscular conditions. Established in 2006, the company's primary offices are situated in Kawasaki, Japan.
4587 Company Deck
4587 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented substantial operational and pipeline progress — notably strong clinical momentum (6 programs entering clinic in 2025, 13 total clinical programs), late-stage radiopharmaceutical programs with NDA timelines, IND acceptances and a healthy cash balance (JPY 28.6 billion). At the same time, key revenue drivers were delayed (notably the myostatin out‑licensing), R&D and headcount-driven costs are increasing (R&D +28% year-over-year; headcount +6.4%), and several high-value deals remain timing-uncertain. Overall, the company appears to be transitioning from a discovery-focused model to a discovery-and-development company with meaningful upside from pipeline advances, but near-term financial performance depends on timing of large upfront deals and execution of planned manufacturing expansions.View all JP:4587 earnings summaries4587 Stock 12 Month Forecast
Average Price Target
¥1,875.00
▲(68.31% Upside)